Fracasso PM - Search Results

1

Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.

Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Luker GD, et al. Among authors: fracasso pm. J Nucl Med. 1997 Mar;38(3):369-72. J Nucl Med. 1997. PMID: 9074520 Free article. Clinical Trial.

2

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ. Fracasso PM, et al. J Clin Oncol. 2000 Mar;18(5):1124-34. doi: 10.1200/JCO.2000.18.5.1124. J Clin Oncol. 2000. PMID: 10694566 Clinical Trial.

3

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP. Fracasso PM, et al. J Clin Oncol. 2001 Jun 15;19(12):2975-82. doi: 10.1200/JCO.2001.19.12.2975. J Clin Oncol. 2001. PMID: 11408492 Clinical Trial.

4

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.

Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Eiblmaier M, et al. Among authors: fracasso pm. J Nucl Med. 2008 Sep;49(9):1472-9. doi: 10.2967/jnumed.108.052316. Epub 2008 Aug 14. J Nucl Med. 2008. PMID: 18703609 Free PMC article.

5

HPLC method for monitoring SDZ PSC 833 in whole blood.

Scott MG, Hock KG, Crimmins DL, Fracasso PM. Scott MG, et al. Among authors: fracasso pm. Clin Chem. 1997 Mar;43(3):505-10. Clin Chem. 1997. PMID: 9068595 Clinical Trial.

6

Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Mortimer JE, et al. Clin Cancer Res. 1996 Jun;2(6):933-9. Clin Cancer Res. 1996. PMID: 9816253

7

Pharmacokinetic study of infusional valspodar.

Ma MK, McLeod HL, Westervelt P, Fracasso PM. Ma MK, et al. Among authors: fracasso pm. J Clin Pharmacol. 2002 Apr;42(4):412-8. J Clin Pharmacol. 2002. PMID: 11936566

8

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

Fracasso PM, Rader JS, Govindan R, Herzog TJ, Arquette MA, Denes A, Mutch DG, Picus J, Tan BR, Fears CL, Goodner SA, Sun SL. Fracasso PM, et al. Ann Oncol. 2002 Nov;13(11):1819-25. doi: 10.1093/annonc/mdf342. Ann Oncol. 2002. PMID: 12419757 Free article. Clinical Trial.

9

Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.

Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Fracasso PM, et al. Clin Cancer Res. 2004 Nov 1;10(21):7220-8. doi: 10.1158/1078-0432.CCR-04-0452. Clin Cancer Res. 2004. PMID: 15534095 Clinical Trial.

10

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.

Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL. Fracasso PM, et al. Br J Cancer. 2005 Jul 11;93(1):46-53. doi: 10.1038/sj.bjc.6602653. Br J Cancer. 2005. PMID: 15942626 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters